Table 2.
Carbamazepine [8,19,40–49] | Ethosuximide [41,45,50–54] | Phenobarbital [20,41,55–58] | Phenytoin [20,41,45,59–64] | Lamotrigine [10,16,18,65–72] | Valproic acid [45,73–79] | Pregabalin [80] | Clonazepam [9,63] | Gabapentin [17,81,82] | Levetiracetam [83–86] | Oxcarbazepine [87–89] | Primidon [41,42,45,58,90] | Topiramate [91–93] | Vigabatrine [21] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of studies included | 12 | 7 | 6 | 9 | 11 | 8 | 1 | 2 | 3 | 4 | 3 | 5 | 3 | 1 |
Publication status | ||||||||||||||
Abstract | 2 | 2 | 0 | 0 | 4 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 0 |
Case report/letter | 5 | 1 | 1 | 2 | 3 | 3 | 0 | 2 | 1 | 0 | 1 | 2 | 0 | 0 |
Full article | 5 | 4 | 5 | 7 | 4 | 5 | 0 | 0 | 1 | 2 | 1 | 3 | 2 | 1 |
Study design | ||||||||||||||
Median number of patients (min−max) | 3 (1–56) | 2 (1–5) | 8 (1–13) | 3 (1–9) | 6 (1–34) | 4 (1–13) | 2 (2–2) | 1 (1–1) | 3 (1–5) | 12.5 (7–14) | 1 (1–3) | 7 (1–12) | 1 (1–3) | 2 (2–2) |
Longitudinal design | 7 | 3 | 3 | 4 | 3 | 5 | 0 | 2 | 0 | 2 | 2 | 3 | 1 | 0 |
Amount of drug in breast milk | ||||||||||||||
Daily dose | 10 | 5 | 2 | 7 | 7 | 8 | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 1 |
Time of drug intake until sampling | 1 | 2 | 4 | 6 | 5 | 4 | 0 | 1 | 1 | 2 | 2 | 0 | 1 | 1 |
Representative milk samples | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
Determination of kinetics | ||||||||||||||
Milk concentrations | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Plasma concentrations | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Active metabolites | 5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2 | N/A | N/A | N/A |
Infant plasma | 7 | 3 | 3 | 5 | 9 | 5 | 1 | 2 | 3 | 3 | 3 | 2 | 1 | 0 |
Endpoints | ||||||||||||||
M : P correctly assessed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
AID correctly assessed | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Values in bold correspond to endpoints.
AID, Absolute infant dose; M : P, Milk : plasma ratio; N/A, Not applicable.